DelveInsight’s, “Hypovolemia – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hypovolemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
• Global coverage
Hypovolemia is a state of an abnormally decreased volume of circulating fluid (plasma) in the body. It may be caused by a rapid and substantial loss of blood or from dehydration due to vomiting, diarrhea, burns, severe environmental fluid losses, or drugs such as diuretics. Lost fluid in patients with dehydration is comprised primarily of plasma rather than whole blood as in the trauma patient.
Hypovolemia can be recognized by an elevated pulse, a diminished blood pressure, and the absence of perfusion as assessed through skin signs (skin turning pale) and/or capillary refill on forehead, lips and nail beds. The patient may feel dizzy, faint, nauseated, or very thirsty.
Agoraphobia is diagnosed based on symptoms and signs a diagnosis. To be diagnosed with agoraphobia, symptoms need to meet certain criteria listed in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM). The DSM is a manual often used by healthcare providers to diagnose mental health conditions.
Psychotherapy, involves meeting with a therapist or other mental health professional on a regular basis to talk about fears and any issues that may be contributing to fears. Cognitive behavioral therapy (CBT) is the most common form of psychotherapy used to treat people with agoraphobia. Certain medications are used to relieve agoraphobia or panic attack symptoms. These include selective serotonin reuptake inhibitors, such as paroxetine (Paxil) or fluoxetine (Prozac), selective serotonin and norepinephrine reuptake inhibitors, such as venlafaxine (Effexor) or duloxetine (Cymbalta), tricyclic antidepressants, such as amitriptyline (Elavil) or nortriptyline (Pamelor), anti-anxiety medications, such as alprazolam (Xanax) or clonazepam (Klonopin).
Hypovolemia Emerging Drugs Chapters
This segment of the Hypovolemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hypovolemia Emerging Drugs
• VBI-S: Vivacelle Bio
VBI-S is in Phase 2 of clinical trial study and is being developed by Vivacelle Bio. The trail got initiated in February 2021 and is expected to get completed by December 2021 with 20 expected enrolled participants.
Further product details are provided in the report……..
Hypovolemia: Therapeutic Assessment
This segment of the report provides insights about the different Hypovolemia drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Hypovolemia
There are approx. 10+ key companies which are developing the therapies for Hypovolemia. The companies which have their Hypovolemia drug candidates in the most advanced stage, i.e. phase II include, Vivacelle Bio.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Hypovolemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Hypovolemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypovolemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypovolemia drugs.
• The companies and academics are working to assess challenges and seek opportunities that could influence Hypovolemia R&D. The therapies under development are focused on novel approaches to treat/improve Hypovolemia.
Hypovolemia Report Insights
• Hypovolemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Hypovolemia Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Hypovolemia drugs?
• How many Hypovolemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypovolemia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypovolemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hypovolemia and their status?
• What are the key designations that have been granted to the emerging drugs?
• Vivacelle Bio
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook